Journal of Clinical Epidemiology
Volume 58, Issue 2 , Pages 162-170 , February 2005

An analysis of administrative data found that proximate clinical event ratios provided a systematic approach to identifying possible iatrogenic risk factors or complications

  • William B. Baine

      Affiliations

    • Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Department of Health and Human Services, 540 Gaither Road, Rockville, MD 20850-6649, USA
    • Corresponding Author InformationCorresponding author. Tel.: 301-427-1504; fax: 301-427-1520.
    • ,
  • Sophia V. Kazakova

      Affiliations

    • Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Department of Health and Human Services, 540 Gaither Road, Rockville, MD 20850-6649, USA
    • Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Suite 492, Hampton House, 624 North Broadway, Baltimore, MD 21205, USA

,Accepted 12 August 2004.

References 

  1. Bureau of Data Management and Strategy, Health Care Financing Administration, US Department of Health and Human Services . Glossary. In: Data users reference guide. Baltimore, MD: The Bureau; 1997;p. 1–7
  2. Granek E, Baker SP, Abbey H, Robinson E, Myers AH, Samkoff JS, et al. Medications and diagnoses in relation to falls in a long-term care facility. J Am Geriatr Soc. 1987;35:503–511
  3. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363–369
  4. Ray WA, Griffin MR, Malcolm E. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med. 1991;151:754–756
  5. Ruthazer R, Lipsitz LA. Antidepressants and falls among elderly people in long-term care. Am J Public Health. 1993;83:746–749
  6. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303–1307
  7. Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998;339:875–882
  8. Arfken CL, Wilson JG, Aronson SM. Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents. Int Psychogeriatr. 2001;13:85–91
  9. Kallin K, Lundin-Olsson L, Jensen J, Nyberg L, Gustafson Y. Predisposing and precipitating factors for falls among older people in residential care. Public Health. 2002;116:263–271
  10. In:  Gluck ME,  Hanson KW editor. Medicare chartbook. 2nd ed.. Menlo Park, CA: Henry J. Kaiser Family Foundation; 2001;p. 23–40
  11. Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality, US Department of Health and Human Services. Medical Expenditure Panel Survey. Available at: http://www.meps.ahrq.gov/MEPSNet/HC/MEPSnetHC.asp. Accessed May 13, 2004.
  12. Bureau of Data Management and Strategy, Health Care Financing Administration, US Department of Health and Human Services . Overview of the Health Care Financing Administration. In: Data users reference guide. Baltimore, MD: The Bureau; 1995;p. 1–16
  13. Bureau of Data Management and Strategy, Health Care Financing Administration, US Department of Health and Human Services . Claims and utilization data. In: Data users reference guide. Baltimore, MD: The Bureau; 1997;p. 1–198
  14. Bureau of Data Management and Strategy, Health Care Financing Administration, US Department of Health and Human Services . Enrollment and eligibility data. In: Data users reference guide. Baltimore, MD: The Bureau; 1997;p. 1–67
  15. American Medical Association . International Classification of Diseases, 9th Revision, clinical modification. ICD-9-CM. 2001. Dover, DE: Medicode; 2000;
  16. Zar JH. Biostatistical analysis. 2nd ed.. Englewood Cliffs, NJ: Prentice-Hall; 1984;p. 369–405
  17. White JS. Tables of normal percentile points. J Am Statistical Assoc. 1970;65:635–638
  18. Levison ME. Pneumonia, including necrotizing pulmonary infections (lung abscess). In:  Braunwald E,  Fauci AS,  Kasper DL,  Hauser SL,  Longo DL,  Jameson JL editor. Harrison's principles of internal medicine. 15th ed.. New York, NY: McGraw-Hill; 2001;p. 1475–1485
  19. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding. A population-based cohort study. Arch Intern Med. 2003;163:59–64
  20. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:478–484
  21. Hill AB. Principles of medical statistics. 9th ed.. New York, NY: Oxford University Press; 1971;p. 312–20
  22. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA. 1979;242:623–632
  23. Lane DA, Kramer MS, Hutchinson TA, Jones JK, Naranjo C. The causality assessment of adverse drug reactions using a Bayesian approach. Pharmaceut Med. 1987;2:265–283
  24. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245
  25. Gallo JJ, Armenian HK, Ford DE, Eaton WW, Khachaturian AS. Major depression and cancer: The 13-year follow-up of the Baltimore Epidemiologic Catchment Area sample. Cancer Causes Control. 2000;11:751–758
  26. Nonsteroidal anti-inflammatory agents. In: Drug facts and comparisons 2003. 57th ed.. St. Louis, MO: Facts & Comparisons; 2002;p. 911–932
  27. Browning CH. Nonsteroidal anti-inflammatory drugs and severe psychiatric side effects. Int J Psychiatry Med. 1996;26:25–34
  28. Juby A, Davis P. Psychological profiles of patients with upper gastrointestinal symptomatology induced by non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 1991;50:211–213
  29. Rugulies R. Depression as a predictor for coronary heart disease. A review and meta-analysis. Am J Prev Med. 2002;23:51–61
  30. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894–1898
  31. Lindal E, Hartharson P, Magnusson J, Alfrethsson H. A 5-year psycho-medical follow-up study of coronary by-pass artery graft patients. Scand J Rehabil Med. 1996;28:27–31
  32. Timberlake N, Klinger L, Smith P, Venn G, Treasure T, Harrison M, et al. Incidence and patterns of depression following coronary artery bypass graft surgery. J Psychosom Res. 1997;43:197–207
  33. Baker RA, Andrew MJ, Schrader G, Knight JL. Preoperative depression and mortality in coronary artery bypass surgery: Preliminary findings. ANZ J Surg. 2001;71:139–142
  34. Peterson JC, Charlson ME, Williams-Russo P, Krieger KH, Pirraglia PA, Meyers BS, et al. New postoperative depressive symptoms and long-term cardiac outcomes after coronary artery bypass surgery. Am J Geriatr Psychiatry. 2002;10:192–198
  35. Bengtsson C, Lennartsson J, Lindquist O, Noppa H, Sigurdsson J. Sleep disturbances, nightmares and other possible central nervous disturbances in a population sample of women, with special reference to those on antihypertensive drugs. Eur J Clin Pharmacol. 1980;17:173–177
  36. Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol. 1985;28(Suppl):55–63
  37. Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA. 1986;255:357–360
  38. Thiessen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman U. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Ann Intern Med. 1990;150:2286–2290
  39. Gerstman BB, Jolson HM, Bauer M, Cho P, Livingston JM, Platt R. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol. 1996;49:809–815
  40. Reid LD, McFarland BH, Johnson RE, Brody KK. Beta-blockers and depression: The more the murkier?. Ann Pharmacother. 1998;32:699–708
  41. Rathmann W, Haastert B, Roseman JM, Giani G. Cardiovascular drug prescriptions and risk of depression in diabetic patients. J Clin Epidemiol. 1999;52:1103–1109
  42. Perez-Stable EJ, Halliday R, Gardiner PS, Baron RB, Hauck WW, Acree M, et al. The effects of propranolol on cognitive function and quality of life: A randomized trial among patients with diastolic hypertension. Am J Med. 2000;108:359–365
  43. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–357
  44. Fogelman J. Verapamil may cause depression, confusion, and impotence. [Letter] Tex Med. 1987;83:8
  45. Biriell C, McEwen J, Sanz E. Depression associated with diltiazem. [Letter] BMJ. 1989;299:796
  46. Kostowski W, Dyr W, Pucilowski O. Activity of diltiazem and nifedipine in some animal models of depression. Pol J Pharmacol Pharm. 1990;42:121–127
  47. Overstreet DH, Pucilowski O, Rezvani AH, Janowsky DS. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Finders Sensitive Line rats as an animal model of depression. Psychopharmacology (Berl). 1995;121:27–37
  48. Patten SB, Williams JV, Love EJ. Self-reported depressive symptoms in association with medication exposures among medical inpatients: A cross-sectional study. Can J Psychiatry. 1995;40:264–269
  49. Kozlovskii VL, Prakh'e IV. Vliianie blokatorov kal'tsievykh kanalov na effekty antidepressantov (Russian). [The influence of calcium channel blockers on antidepressant effects.] Eksp Klin Farmakol. 1996;59:9–11
  50. Srivastava SK, Nath C. The differential effects of calcium channel blockers in the behavioural despair test in mice. Pharmacol Res. 2000;42:293–297
  51. Paolucci S, Antonucci G, Grasso MG, Morelli D, Troisi E, Coiro P, et al. Post-stroke depression, antidepressant treatment and rehabilitation results. A case–control study. Cerebrovasc Dis. 2001;12:264–271
  52. Turner-Stokes L. Poststroke depression: Getting the full picture. Lancet. 2003;361:1757–1758
  53. McDonnell CO, Bailey I, Stumpf T, Walsh TN, Johnson CD. The effect of cholecystectomy on plasma cholecystokinin. Am J Gastroenterol. 2002;97:2189–2192
  54. Hernando F, Fuentes JA, Roques BP, Ruiz-Gayo M. The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Eur J Pharmacol. 1994;261:257–263
  55. Wells AS, Read NW, Uvnas-Moberg K, Alster P. Influences of fat and carbohydrate on postprandial sleepiness, mood, and hormones. Physiol Behav. 1997;61:679–686
  56. Wells AS, Read NW, Fried M, Borovicka J, D'Amato M. Effects of a specific CCK-A antagonist, Loxiglumide on postprandial mood and sleepiness. J Psychopharmacol. 1997;11:241–246
  57. Biagi RW, Bapat BN. Intrahepatic obstructive jaundice from amitriptyline. Br J Psychiatry. 1967;113:1113–1114
  58. Larrey D, Amouyal G, Pessayre D, Degott C, Danne O, Machayekhi JP, et al. Amitriptyline-induced prolonged cholestasis. Gastroenterology. 1988;94:200–203
  59. Baine WB, Yu W, Summe JP. Epidemiologic trends in the hospitalization of elderly Medicare patients for pneumonia, 1991–1998. Am J Public Health. 2001;91:1121–1123
  60. Langmore SE, Skarupski KA, Park PS, Fries BE. Predictors of aspiration pneumonia in nursing home residents. Dysphasia. 2002;17:298–307
  61. Ackerman DL, Ünutzer J, Greenland S, Gitlin M. Inpatient treatment of depression and associated hospital charges. Pharmacoepidemiol Drug Saf. 2002;11:219–227
  62. Bonhomme N. Involvement of serotonin and dopamine in the mechanism of action of novel antidepressant drugs: A review. J Clin Psychopharmacol. 1998;18:447–454
  63. Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry. 1998;59(Suppl 5):60–64
  64. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol. 2000;405:365–373
  65. Zangen A, Nakash R, Overstreet DH, Yadid G. Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology (Berl). 2001;155:434–439
  66. Kessler JP, Jean A. Inhibition of the swallowing reflex by local application of serotonergic agents into the nucleus of the solitary tract. Eur J Pharmacol. 1985;118:77–85
  67. Kessler JP, Jean A. Effect of catecholamines on the swallowing reflex after pressure microinjections into the lateral solitary complex of the medulla oblongata. Brain Res. 1986;386:69–77
  68. Kessler JP, Jean A. Inhibitory influence of monoamines and brainstem monoaminergic regions on the medullary swallowing reflex. Neurosci Lett. 1986;65:41–46
  69. Sigala S, Missale G, Raddino R, Cestari R, Lojacono L, Missale C, et al. Opposing roles for D-1 and D-2 dopamine receptors in the regulation of lower esophageal sphincter motility in the rat. Life Sci. 1994;54:1035–1045
  70. Valenzuela JE, Dooley CP. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol Suppl. 1984;96:127–136
  71. Shannon M, Lovejoy FH. Pulmonary consequences of severe tricyclic antidepressant ingestion. J Toxicol Clin Toxicol. 1987;25:443–461
  72. Roy TM, Ossorio MA, Cipolla LM, Fields CL, Snider HL, Anderson WH. Pulmonary complications after tricyclic antidepressant overdose. Chest. 1989;96:852–856
  73. Varnell RM, Godwin JD, Richardson ML, Vincent JM. Adult respiratory distress syndrome from overdose of tricyclic antidepressants. Radiology. 1989;170:667–670
  74. Antidepressants. In: Drug facts and comparisons 2003. 57th ed.. St. Louis, MO: Facts & Comparisons; 2002;p. 976–1021
  75. Schwartz JB. Clinical pharmacology. In:  Hazzard WR,  Blass JP,  Ettinger WH,  Halter JB,  Ouslander JG editor. Principles of geriatric medicine and gerontology. 4th ed.. New York, NY: McGraw-Hill; 1999;p. 302–331

PII: S0895-4356(04)00198-2

doi: 10.1016/j.jclinepi.2004.08.002

Journal of Clinical Epidemiology
Volume 58, Issue 2 , Pages 162-170 , February 2005

Article Tools